Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA

被引:31
作者
Bonanno, Patricia Vella [1 ]
Bucsics, Anna [2 ]
Simoens, Steven [3 ]
Martin, Antony P. [4 ]
Oortwijn, Wija [5 ]
Gulbinovic, Jolanta [6 ]
Rothe, Celia [7 ]
Timoney, Angela [1 ,8 ]
Ferrario, Alessandra [9 ,10 ]
Gad, Mohamed [11 ]
Salem, Ahmed [12 ]
Hoxha, Iris [13 ]
Sauermann, Robert [14 ]
Kamusheva, Maria [15 ]
Dimitrova, Maria [15 ]
Petrova, Guenka [15 ]
Laius, Ott [16 ]
Selke, Gisbert [17 ]
Kourafalos, Vasilios [18 ]
Yfantopoulos, John [19 ]
Magnusson, Einar [20 ]
Joppi, Roberta [21 ]
Jakupi, Arianit [22 ]
Bochenek, Tomasz [7 ]
Wladysiuk, Magdalene [23 ]
Furtado, Claudia [24 ]
Markovic-Pekovic, Vanda [25 ,26 ]
Mardare, Ileana [27 ]
Meshkov, Dmitry [28 ]
Furst, Jurij [29 ]
Tomek, Dominik [30 ]
Cortadellas, Merce Obach [31 ]
Zara, Corrine [31 ]
Haycox, Alan [4 ]
Campbell, Stephen [32 ,33 ]
Godman, Brian [1 ,4 ,34 ,35 ]
机构
[1] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow G4 0RE, Lanark, Scotland
[2] Mech Coordinated Access Orphan Med Prod MoCA, Brussels, Belgium
[3] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium
[4] Univ Liverpool, Hlth Econ Ctr, Sch Management, Liverpool, Merseyside, England
[5] Radboud Univ Nijmegen, Dept Hlth Evidence, Med Ctr, Nijmegen, Netherlands
[6] Vilnius Univ, Dept Pathol Forens Med & Pharmacol, Inst Biomed Sci, Fac Med, Vilnius, Lithuania
[7] Jagiellonian Univ, Dept Drug Management, Fac Hlth Sci, Coll Med, Krakow, Poland
[8] NHS Lothian, Edinburgh, Midlothian, Scotland
[9] Harvard Med Sch, Div Hlth Policy & Insurance Res, Dept Populat Med, Boston, MA 02115 USA
[10] Harvard Pilgrim Hlth Care Inst, Boston, MA USA
[11] Imperial Coll, Global Hlth & Dev Grp, London, England
[12] IQVIA, Brussels, Belgium
[13] Univ Med, Dept Pharm, Fac Med, Tirana, Albania
[14] Hauptverband OsterreichischenSozialversicherungst, Vienna, Austria
[15] Med Univ Sofia, Fac Pharm, Dept Org & Econ Pharm, Sofia, Bulgaria
[16] State Agcy Med, Tartu, Estonia
[17] Wissenschaftliches Inst AOK WidO, Berlin, Germany
[18] EOPYY Natl Org Provis Healthcare Serv, Athens, Greece
[19] Univ Athens, Sch Econ & Polit Sci, Athens, Greece
[20] Minist Hlth, Dept Hlth Serv, Reykjavik, Iceland
[21] Azienda Sanit Locale Verona, Pharmaceut Drug Dept, Verona, Italy
[22] UBT Higher Educ Inst, Prishtina, Kosovo
[23] HTA Consulting, Krakow, Poland
[24] INFAMED, Pharmaceut Div, Lisbon, Portugal
[25] Minist Hlth & Social Welf, Banja Luka, Republic Of Srp, Bosnia & Herceg
[26] Univ Banja Luka, Fac Med, Dept Social Pharm, Banja Luka, Republic Of Srp, Bosnia & Herceg
[27] Carol Davila Univ Med & Pharm Bucharest, Fac Med, Publ Hlth & Management Dept, Bucharest, Romania
[28] Natl Res Inst Publ Hlth, Moscow, Russia
[29] Hlth Insurance Inst, Ljubljana, Slovenia
[30] Slovak Med Univ, Fac Med, Bratislava, Slovakia
[31] Catalan Hlth Serv, Drug Terr Act Unit, Barcelona, Spain
[32] Univ Manchester, Div Populat Hlth Hlth Serv Res & Primary Care, Ctr Primary Care, Manchester, Lancs, England
[33] Univ Manchester, NIHR Greater Manchester Patient Safety Translat R, Sch Hlth Sci, Manchester, Lancs, England
[34] Karolinska Inst, Div Clin Pharmacol, Stockholm, Sweden
[35] Sefako Makgatho Hlth Sci Univ, Sch Pharm, Dept Publ Hlth Pharm & Management, Garankuwa, South Africa
关键词
EUnetHTA; joint collaboration on HTA; cross border agreements; Member States; European legislation; MANAGED ENTRY AGREEMENTS; RARE DISEASES; MEDICINES; DRUGS; AVAILABILITY; PRICES; COST; CARE; IMPLEMENTATION; REIMBURSEMENT;
D O I
10.1080/14737167.2019.1575730
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: In January 2018 the European Commission published a Proposal for a Regulation on Health Technology Assessment (HTA): 'Proposal for a Regulation on health technology assessment and amending Directive 2011/24/EU'. A number of stakeholders, including some Member States, welcomed this initiative as it was considered to improve collaboration, reduce duplication and improve efficiency. There were however a number of concerns including its legal basis, the establishment of a single managing authority, the preservation of national jurisdiction over HTA decision-making and the voluntary/mandatory uptake of joint assessments by Member States. Areas covered: This paper presents the consolidated views and considerations on the original Proposal as set by the European Commission of a number of policy makers, payers, experts from pricing and reimbursement authorities and academics from across Europe. Expert commentary: The Proposal has since been extensively discussed at Council and while good progress has been achieved, there are still divergent positions. The European Parliament gave a number of recommendations for amendments. If the Proposal is approved, it is important that a balanced, improved outcome is achieved for all stakeholders. If not approved, the extensive contribution and progress attained should be sustained and preserved, and the best alternative solutions found.
引用
收藏
页码:251 / 261
页数:11
相关论文
共 86 条
[1]   The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts [J].
Abboud, Camille ;
Berman, Ellin ;
Cohen, Adam ;
Cortes, Jorge ;
DeAngelo, Daniel ;
Deininger, Michael ;
Devine, Steven ;
Druker, Brian ;
Fathi, Amir ;
Jabbour, Elias ;
Jagasia, Madan ;
Kantarjian, Hagop ;
Khoury, Jean ;
Laneuville, Pierre ;
Larson, Richard ;
Lipton, Jeffrey ;
Moore, Joseph O. ;
Mughal, Tariq ;
O'Brien, Susan ;
Pinilla-Ibarz, Javier ;
Quintas-Cardama, Alfonso ;
Radich, Jerald ;
Reddy, Vishnu ;
Schiffer, Charles ;
Shah, Neil ;
Shami, Paul ;
Silver, Richard T. ;
Snyder, David ;
Stone, Richard ;
Talpaz, Moshe ;
Tefferi, Ayalew ;
Van Etten, Richard A. ;
Wetzler, Meir ;
Abruzzese, Elisabetta ;
Apperley, Jane ;
Breccia, Massimo ;
Byrne, Jenny ;
Cervantes, Francisco ;
Chelysheva, Ekaterina ;
Clark, R. E. ;
de Lavallade, Hugues ;
Dyagil, Iryna ;
Gambacorti-Passerini, Carlo ;
Goldman, John ;
Haznedaroglu, Ibrahim ;
Hjorth-Hansen, Henrik ;
Holyoake, Tessa ;
Huntly, Brian ;
le Coutre, Philipp ;
Lomaia, Elza .
BLOOD, 2013, 121 (22) :4439-4442
[2]  
Annemans L., 2017, USE REAL WORLD DATA
[3]  
[Anonymous], 2017, INTEGRATE HTA REPORT
[4]  
[Anonymous], VALUE PHARM PRICING
[5]  
[Anonymous], 2018, EUNETHTA HTA CORE MO
[6]  
[Anonymous], STRAT EU COOP HLTH T
[7]  
[Anonymous], 2008, Consolidated Version of the Treaty on European Union, C 115/13
[8]  
[Anonymous], WE DONT TALK VALUE C
[9]  
[Anonymous], OFFICIAL J EUROPEAN
[10]  
[Anonymous], 283 KCE